Compounds Acting on Glucose Absorption

1.2.1 Uses and 1.2.2 Glucose 1.2.3 Lipid 1.2.4 Blood 1.3.1 Dosage and 1.3.2 Pharmacokinetic 1.4 Toxic and Side 1.5 Interactions with Other 1.6 Clinical 1.6.1 Healthy 1.6.2 Type-I Diabetes 1.6.3 Type-II Diabetes 2.2.1 Glycogen Metabolism 160 2.2.2 Lipid 2.3 Uses and 2.4.2 Plasma 2.5 Toxic and Side 2.6 Interaction with Other 2.7 Clinical 2.7.1 Healthy 2.7.2 Type-I Diabetes 2.7.3 Type-II Diabetes Guar is derived from the endosperm of the seed Cyamopsis psoraloides (C. tetragonoloba). It contains...

S

Mean plasma glucose and plasma insulin responses to oral glucose before ( ) and after (O) 1 week of metformin treatment in NIDDM patients. Plasma glucose concentrations decreased significantly. (Source Fantus and Brosseau, 1986.) diabetics. Despite the controversy about hyperinsulinaemia as an independent risk factor for coronary heart disease, there is no doubt of its relationship to other risk factors (Campbell, 1990). In contrast to sulphonylureas, the non-insulinotropic biguanides...

Info

Source Hanefeld el al. (1990). markedly reduced, making acarbose the drug of choice for treating the metabolic syndrome after dietary failure (Hanefeld et al., 1990). In long-term trials, acarbose also lowered serum triglycerides and VLDL significantly, while cholesterol levels were not affected (Leonhardt et al., 1991). The therapeutic effects of acarbose and biguanides have been compared in Type-II diabetics (Pagano and Cavallo-Perin, 1990) and found to be...

Pharmacokinetics

The development of aldose reductase inhibitors as useful drugs is actually at the stage of evaluation of their pharmacodynamic benefit. Data on the pharmacokinetic properties of these drugs are therefore rather scarce. In addition, owing to their chemical heterogeneity, no common principles can be established. Tolrestat is absorbed after oral administration to the extent of about 70 in man. Data on different animal models give higher values (Dvornik et al., 1988). The maximal plasma level after...